A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors

by Filippo de Braud, Jean-Pascal H. Machiels, Daniela Boggiani, Sylvie W.H. Rottey, Matteo Duca, Marie Laruelle, Stefania Salvagni, Silvia Damian, Lore D.F. Lapeire, Marcello Tiseo, Alexandre Dermine, Mahmoud Ould-Kaci, Juergen Braunger, Juliane Rascher, Daniela Fischer, Josef Hoefler, Gabriella L. Mariani, Sara Cresta
Published 2020-05-01